Farmaceutisch concern
Exela
Een concern van 4 bedrijven met 15 geneesmiddelen in 3 landen.
Concernstructuur
4 bedrijven in 2 landen
Verenigde Staten3
Singapore1
Prognia stelt concerns samen uit de namen die toezichthouders publiceren en uit koppelingen tussen bedrijven; het is geen officiële concernstructuur.
Geneesmiddelen
Alle geneesmiddelen van alle bedrijven in het concern, actuele eerst.
15 geneesmiddelen
| Geneesmiddel | Werkzame stof | Land | Status | Toelating |
|---|---|---|---|---|
| AKOVAZ25mg/5ml (5mg/ml) | 50mg/ml (50mg/ml) · Solution | Ephedrine | Verenigde Staten | In de handel | 2016 |
| ANEXTROZOLE FILM-COATED TABLET 1 mg1.0mg · Tablet, film coated | Anastrozole | Singapore | Toegelaten | 2017 |
| BLOXIVERZ10mg/10ml (1mg/ml) | 5mg/10ml (0.5mg/ml) | 5mg/5ml (1mg/ml) · Solution | Neostigmine | Verenigde Staten | In de handel | 2013 |
| CAFFEINE CITRATE30mg base/3ml (eq 10mg base/ml) · Solution | Caffeine | Verenigde Staten | In de handel | 2006 |
| DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%125MG/125ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG/250ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Diltiazem | Verenigde Staten | Niet in de handel | 2021 |
| ELCYS2500mg/50ml (50mg/ml) | 500mg/10ml (50mg/ml) · Solution | Cysteinum | Verenigde Staten | In de handel | 2019 |
| FENTANYL CITRATE2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG BASE/100ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Fentanyl | Verenigde Staten | Niet in de handel | 2023 |
| GANZYK-RTU500mg/250ml (2mg/ml) · Solution | Ganciclovir | Verenigde Staten | Niet in de handel | 2017 |
| GLYRX-PF0.2mg/ml (0.2mg/ml) | 0.4mg/2ml (0.2mg/ml) | 0.6mg/3ml (0.2mg/ml) | 1mg/5ml (0.2mg/ml) · Solution | Glycopyrronium | Verenigde Staten | In de handel | 2018 |
| MIDAZOLAM IN 0.8% SODIUM CHLORIDE100MG/100ML (1MG/ML) | 50MG/50ML (1MG/ML) | 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Midazolam | Verenigde Staten | In de handel | 2022 |
| NIPRIDE RTU IN SODIUM CHLORIDE 0.9%10MG/50ML (0.2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG/100ML (0.2MG/ML) | 50MG/100ML (0.5MG/ML) · Solution | Nitroprusside | Verenigde Staten | In de handel | 2017 |
| POTASSIUM ACETATE2meq/ml · Injectable | Potassium acetate | Verenigde Staten | In de handel | 1984 |
| VAZCULEP100mg/10ml (10mg/ml) | 10mg/ml (10mg/ml) | 50mg/5ml (10mg/ml) · Solution | Phenylephrine | Verenigde Staten | Niet in de handel | 2014 |
| ARIGAL 250MG/2.5ML | Argatroban | Saoedi-Arabië | Toegelaten | |
| ARIGAL 50MG/50ML | Argatroban | Saoedi-Arabië | Toegelaten |